What do systematic reviews say?

Intervention not reported

• Xpert MTB/XDR for detection of pulmonary tuberculosis and resistance to isoniazid, fluoroquinolones, ethionamide, and… 2022 · Cochrane Headline outcomes only
  no estimate extracted
  2 studies · 381 participants
  High

Intervention not reported

• Xpert MTB/XDR for detection of pulmonary tuberculosis and resistance to isoniazid, fluoroquinolones, ethionamide, and… 2022 · Cochrane Headline outcomes only
  no estimate extracted
  2 studies · 640 participants
  Moderate

Intervention not reported

• Xpert MTB/XDR for detection of pulmonary tuberculosis and resistance to isoniazid, fluoroquinolones, ethionamide, and… 2022 · Cochrane Headline outcomes only
  no estimate extracted
  2 studies · 640 participants
  Moderate

Intervention not reported

The review found no eligible studies for this question.

• Xpert MTB/XDR for detection of pulmonary tuberculosis and resistance to isoniazid, fluoroquinolones, ethionamide, and… 2022 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Intervention not reported

• Xpert MTB/XDR for detection of pulmonary tuberculosis and resistance to isoniazid, fluoroquinolones, ethionamide, and… 2022 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 167 participants
  Very low

Intervention not reported

• Xpert MTB/XDR for detection of pulmonary tuberculosis and resistance to isoniazid, fluoroquinolones, ethionamide, and… 2022 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 167 participants
  Very low

Intervention not reported

• Xpert MTB/XDR for detection of pulmonary tuberculosis and resistance to isoniazid, fluoroquinolones, ethionamide, and… 2022 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 267 participants
  Very low

Intervention not reported

• Xpert MTB/XDR for detection of pulmonary tuberculosis and resistance to isoniazid, fluoroquinolones, ethionamide, and… 2022 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 267 participants
  Very low

Intervention not reported

The review found no eligible studies for this question.

• Xpert MTB/XDR for detection of pulmonary tuberculosis and resistance to isoniazid, fluoroquinolones, ethionamide, and… 2022 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Intervention not reported

• Xpert MTB/XDR for detection of pulmonary tuberculosis and resistance to isoniazid, fluoroquinolones, ethionamide, and… 2022 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 65 participants
  Low

Intervention not reported

• Xpert MTB/XDR for detection of pulmonary tuberculosis and resistance to isoniazid, fluoroquinolones, ethionamide, and… 2022 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 65 participants
  Low

Intervention not reported

• Xpert MTB/XDR for detection of pulmonary tuberculosis and resistance to isoniazid, fluoroquinolones, ethionamide, and… 2022 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 425 participants
  High

Intervention not reported

• Xpert MTB/XDR for detection of pulmonary tuberculosis and resistance to isoniazid, fluoroquinolones, ethionamide, and… 2022 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 425 participants
  High

Intervention not reported

The review found no eligible studies for this question.

• Xpert MTB/XDR for detection of pulmonary tuberculosis and resistance to isoniazid, fluoroquinolones, ethionamide, and… 2022 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Intervention not reported

• Xpert MTB/XDR for detection of pulmonary tuberculosis and resistance to isoniazid, fluoroquinolones, ethionamide, and… 2022 · Cochrane Headline outcomes only
  no estimate extracted
  2 studies · 756 participants
  Moderate

Intervention not reported

• Xpert MTB/XDR for detection of pulmonary tuberculosis and resistance to isoniazid, fluoroquinolones, ethionamide, and… 2022 · Cochrane Headline outcomes only
  no estimate extracted
  2 studies · 756 participants
  Moderate

Intervention not reported

• Xpert MTB/XDR for detection of pulmonary tuberculosis and resistance to isoniazid, fluoroquinolones, ethionamide, and… 2022 · Cochrane Headline outcomes only
  no estimate extracted
  2 studies · 327 participants
  Moderate

Early systemic postnatal corticosteroids vs placebo or no treatment

Early systemic postnatal corticosteroids showed no clear difference in mortality at latest reported age compared with placebo or no treatment (high certainty).

• Early (< 7 days) systemic postnatal corticosteroids for prevention of bronchopulmonary dysplasia in preterm infants 2021 · Cochrane Headline outcomes only
  RR 0.95 [0.85, 1.06]
  31 studies · 4373 participants
  High

Early systemic postnatal corticosteroids vs placebo or no treatment

Early systemic postnatal corticosteroids probably leads to lower BPD (36 weeks' PMA) compared with placebo or no treatment (moderate certainty).

• Early (< 7 days) systemic postnatal corticosteroids for prevention of bronchopulmonary dysplasia in preterm infants 2021 · Cochrane Headline outcomes only
  RR 0.8 [0.73, 0.88]
  26 studies · 4167 participants
  Moderate

Early systemic postnatal corticosteroids vs placebo or no treatment

Early systemic postnatal corticosteroids leads to lower mortality or BPD at 36 weeks' PMA compared with placebo or no treatment (high certainty).

• Early (< 7 days) systemic postnatal corticosteroids for prevention of bronchopulmonary dysplasia in preterm infants 2021 · Cochrane Headline outcomes only
  RR 0.89 [0.84, 0.94]
  26 studies · 4167 participants
  High